Mesoblast (MESO) Reports Q2 Loss of $0.06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Mesoblast Reports on First Half and Second Quarter Financial Results
February 16, 2016 4:41 PM ESTMELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB) (Nasdaq: MESO) today reported financial results and operational highlights for the 1H/2Q ended 31 December 2015.
Financial Highlights (USD)
At 31 December 2015, the Company had cash reserves of $120.8 million.Â
Operating cash outflow for the second quarter of 2016 was US$19.8 million, a reduction of over 25% in comparison to the first quarter of 2016 (US$28.1 million) and the fourth quarter of 2015 (US$27.3 million). This reduction was... More
Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis
February 16, 2016 6:00 AM ESTNEW YORK and MELBOURNE, Australia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB) (Nasdaq: MESO) today announced results from the first cohort of its ongoing Phase 2 trial in rheumatoid arthritis (RA) patients who have previously failed one or more biologic agents. Top line results showed that a single intravenous infusion of the lower dose of Mesoblasts proprietary Mesenchymal Precursor Cell (MPC) product candidate, MPC-300-IV, was safe and resulted in early and... More
